Sun Pharma gets FDA approval for diabetes generic drug

Fri Jul 12, 2013 8:40am IST

Related Topics

Stocks

   

REUTERS - Sun Pharmaceutical Industries(SUN.NS) said on Friday it has received final approval from the United States Food and Drug Administration (FDA) to launch the generic version of Novo Nordisk's (NOVOb.CO) Prandin diabetes drug.

Prandin, known chemically as repaglinide, and its combination with the commonly prescribed type 2 diabetes drug metformin, sold as PrandiMet, had sales of about $200 million in 2012 for Novo.

Sun Pharma said it would be eligible for a 180-day marketing exclusivity in the United States for the drug.

A U.S. appeals court last month found the patent on Novo's Prandin diabetes drug in combination with metformin to be invalid, paving the way for the introduction of a generic version of the drug.

(Reporting by Sumeet Chatterjee in MUMBAI; Editing by Supriya Kurane)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Fuelling Change

REUTERS SHOWCASE

NSEL Fraud

NSEL Fraud

Govt orders Financial Tech to absorb NSEL, liabilities  Full Article 

Quarterly Result

Quarterly Result

HDFC Bank net profit up 20 percent, lags estimates.  Full Article 

JLR China

JLR China

JLR sees 20 percent growth in China sales this year - exec  Full Article 

China Economy

China Economy

China's growth slowest since global crisis, annual target at risk  Full Article 

Coal Reforms

Coal Reforms

Factbox - India pushes ahead with coal reforms  Full Article 

Apple Result

Apple Result

Apple's iPhone sales beat Street but iPad volumes slide  Full Article 

Airport Accident

Airport Accident

Total CEO de Margerie killed in Moscow business jet accident  Full Article 

Nadella's Paycheck

Nadella's Paycheck

New Microsoft CEO Nadella's pay tops $80 mln with big stock awards.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage